Hepatocellular Carcinoma

Jorge A. Marrero, Shawn Pelletier

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

It is expected that the number of patients who have HCC will continue to increase over the next 2 decades. Currently, most patients who have HCC present with advanced disease, and the overall survival has improved minimally over the last 20 years, making early detection crucial. Patients who have cirrhosis are at the highest risk for developing HCC and constitute the population in which surveillance should be performed. AFP and ultrasound are the major means of surveillance, although evidence of their efficacy is lacking. Once HCC is diagnosed, staging is critical to determine prognosis and the treatment plan. The BCLC is the preferred method for staging and for guiding therapy. Resection, transplantation, and percutaneous ablation are considered curative because of their excellent 5-year survival rates. Currently, there is no standard therapy for advanced HCC.

Original languageEnglish (US)
Pages (from-to)339-351
Number of pages13
JournalClinics in Liver Disease
Volume10
Issue number2
DOIs
StatePublished - May 2006

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Therapeutics
Survival Rate
Transplantation
Survival
Population

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatocellular Carcinoma. / Marrero, Jorge A.; Pelletier, Shawn.

In: Clinics in Liver Disease, Vol. 10, No. 2, 05.2006, p. 339-351.

Research output: Contribution to journalArticle

Marrero, Jorge A. ; Pelletier, Shawn. / Hepatocellular Carcinoma. In: Clinics in Liver Disease. 2006 ; Vol. 10, No. 2. pp. 339-351.
@article{04fafc3d01b0446498f1bf9282743801,
title = "Hepatocellular Carcinoma",
abstract = "It is expected that the number of patients who have HCC will continue to increase over the next 2 decades. Currently, most patients who have HCC present with advanced disease, and the overall survival has improved minimally over the last 20 years, making early detection crucial. Patients who have cirrhosis are at the highest risk for developing HCC and constitute the population in which surveillance should be performed. AFP and ultrasound are the major means of surveillance, although evidence of their efficacy is lacking. Once HCC is diagnosed, staging is critical to determine prognosis and the treatment plan. The BCLC is the preferred method for staging and for guiding therapy. Resection, transplantation, and percutaneous ablation are considered curative because of their excellent 5-year survival rates. Currently, there is no standard therapy for advanced HCC.",
author = "Marrero, {Jorge A.} and Shawn Pelletier",
year = "2006",
month = "5",
doi = "10.1016/j.cld.2006.05.012",
language = "English (US)",
volume = "10",
pages = "339--351",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Hepatocellular Carcinoma

AU - Marrero, Jorge A.

AU - Pelletier, Shawn

PY - 2006/5

Y1 - 2006/5

N2 - It is expected that the number of patients who have HCC will continue to increase over the next 2 decades. Currently, most patients who have HCC present with advanced disease, and the overall survival has improved minimally over the last 20 years, making early detection crucial. Patients who have cirrhosis are at the highest risk for developing HCC and constitute the population in which surveillance should be performed. AFP and ultrasound are the major means of surveillance, although evidence of their efficacy is lacking. Once HCC is diagnosed, staging is critical to determine prognosis and the treatment plan. The BCLC is the preferred method for staging and for guiding therapy. Resection, transplantation, and percutaneous ablation are considered curative because of their excellent 5-year survival rates. Currently, there is no standard therapy for advanced HCC.

AB - It is expected that the number of patients who have HCC will continue to increase over the next 2 decades. Currently, most patients who have HCC present with advanced disease, and the overall survival has improved minimally over the last 20 years, making early detection crucial. Patients who have cirrhosis are at the highest risk for developing HCC and constitute the population in which surveillance should be performed. AFP and ultrasound are the major means of surveillance, although evidence of their efficacy is lacking. Once HCC is diagnosed, staging is critical to determine prognosis and the treatment plan. The BCLC is the preferred method for staging and for guiding therapy. Resection, transplantation, and percutaneous ablation are considered curative because of their excellent 5-year survival rates. Currently, there is no standard therapy for advanced HCC.

UR - http://www.scopus.com/inward/record.url?scp=33846263092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846263092&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2006.05.012

DO - 10.1016/j.cld.2006.05.012

M3 - Article

C2 - 16971265

AN - SCOPUS:33846263092

VL - 10

SP - 339

EP - 351

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 2

ER -